Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Man Group plc slashed its stake in Regeneron Pharmaceuticals by over 40%, unloading 24,377 shares in Q4. Despite this selloff, Regeneron’s stock climbed 3.2%, shrugging off investor jitters like a ...

Key Takeaways The S&P 500 slipped 0.4% on Tuesday, May 20, snapping a six-day winning streak as investors' confidence on ...

Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

REGN's trading volume is 167,455 compared to the stock's average volume of 1,044,709 ... and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and ...

Finally, The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research report on Wednesday.

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising ...